A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-3614
Latest Information Update: 11 May 2022
At a glance
- Drugs MK 3614 (Primary)
- Indications Hypertension
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 19 Apr 2010 New trial record